Translational research, bringing new laboratory findings quickly to improve prevention, treatment, quality of life, and survival for breast cancer patients, has been the focus of the team now forming the Baylor Breast Center for 25 years. During the first ten years of our SPORE, our tumor bank which made much of this rapid translation possible became a national resource, while basic cell and molecular biology research suggested new clinical implications for endocrine and chemo-therapy resistance, breast cancer prevention, metastasis, development of premalignant lesions, and roles for tumor suppressor genes BRCA-1 and -2 in DNA repair. Developmental projects ranged even further in seeking new translational possibilities. In this SPORE renewal, we build on the results developed in our earlier work and on new findings and new technologies, in several directions. (1) Compelling new data indicates that cross-talk from growth factor and stress pathways to the estrogen receptor and its co-activators may lie at the root of clinical resistance to tamoxifen, and suggests feasible clinical interventions. We will lay the preclinical groundwork for definitive trials and examine in clinical specimens the prognostic and predictive value of key intermediates from these pathways. (2) Our gene expression array studies offer the promise of a rational risk classification of DCIS. We will assess key markers indicated by these studies on a unique series of DCIS specimens, to evaluate their potential to predict progression to invasive cancer. (3) Tamoxifen can prevent ER-positive breast cancer in many high-risk women, but does nothing against the emergence of ER-negative disease. Based on ongoing treatment studies plus our own laboratory data, we now propose preclinical studies and an early clinical trial of the receptor tyrosine kinase inhibitor Iressa in chemoprevention of breast cancer in women at risk. (4) Our discovery that a single hypersensitive estrogen receptor mutant is found in many hyperplasias and in most node-positive breast cancers, but not in normal tissue, suggests that this mutant could be not only a powerful risk indicator but a uniquely specific treatment target. We will explore both possibilities. (5) Our preliminary expression array data in responders vs. non-responders to neoadjuvant Taxotere implies that the gene expression profile might strongly predict clinical sensitivity or resistance. We will test in a randomized trial the ability of expression profiles to distinguish Taxotere from AC sensitivity, and confirm markers from these profiles in sets of retrospective clinical specimens. (6) Although important parts of our unique breast Tissue Resource were lost in last year's floods, much remains, and we propose important new accessions to further enhance this critical resource. (7) Pathology, Biostatistics, and Administrative Cores will also support key aspects of the proposed work. (8) Our highly successful Developmental Projects Program and Career Development Program will continue to encourage new ideas and new investigators in translational breast cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058183-12S4
Application #
7291291
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kuzmin, Igor A
Project Start
1992-09-30
Project End
2007-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
12
Fiscal Year
2006
Total Cost
$149,979
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications